Vitamin D status in patients with Behcet's Disease by Karatay, Saliha et al.
CLINICAL SCIENCE
Vitamin D status in patients with Behcet’s Disease
Saliha Karatay,I Kadir Yildirim,I Ali Karakuzu,II Ahmet Kiziltunc,III Ragip Ismail Engin,II Yonca Bavli Eren,I
Akin AktasII
IDepartment of Physical Medicine and Rehabilitation, Ataturk University, Medical Faculty, Erzurum-Turkey. IIDepartment of Dermatology, Ataturk
University, Medical Faculty, Erzurum-Turkey. IIIDepartment of Biochemistry, Ataturk University, Medical Faculty, Erzurum-Turkey.
OBJECTIVES: This study investigated the serum 25-hydroxyvitamin D levels of patients with Behcet’s Disease.
DESIGN ANDMETHODS: Thirty-two patients with Behcet’s Disease and 31 matched healthy controls were enrolled in
this study. The erythrocyte sedimentation rate (ESR) and the levels of C-reactive protein (CRP), serum 25-
hydroxyvitamin D, calcium (Ca), phosphate (P), and total alkaline phosphatase (ALP) were measured in both groups.
RESULTS: There were no significant differences between the two groups regarding demographic data. The serum 25-
hydroxyvitamin D levels of patients and controls were 13.76 (range: 4.00-35.79) and 18.97 (range: 12.05-36.94) ng/ml,
respectively. In patients with Behcet’s Disease, 25-hydroxyvitamin D values were significantly lower than those of the
healthy controls (p,0.001). Serum Ca, P, and ALP levels were similar in both groups. Serum ESR and CRP levels were
significantly higher in patients than controls (p,0.05). There was no correlation between 25-hydroxyvitamin D levels
and age, body mass index (BMI), disease duration, ESR, or CRP levels. Multivariate regression analysis parameters
showed that smoking, alcohol intake, and use of colchicine were themain predictors of 25-hydroxyvitamin D levels. Of
the parameters studied, the largest impact was due to colchicine therapy (p,0.001). We did not find a significant
relationship between the use of corticosteroids and 25-hydroxyvitamin D levels.
CONCLUSION: Our results suggest that serum 25-hydroxyvitamin D levels are decreased in patients with Behcet’s
Disease. Smoking, alcohol intake, and use of colchicine appear to affect vitamin D levels.
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INTRODUCTION
Behcet’s Disease is a chronic inflammatory disease with
exacerbations and remissions characterized by recurrent
orogenital ulcerations, ocular manifestations, arthritis, and
vasculitis. In addition, neurological and large vessel involve-
ment can occur in some cases.1 Occasionally it appears
associated with ankylosing spondilitis.2 The infiltration of
lymphocytes and monocytes through small veins without
microscopic changes in the vessel walls are major features in
the inflamed tissues.3 The etiology and pathogenesis of
Behcet’s Disease have not been clearly defined. However,
several genetic, environmental, and immunological factors
have been suggested as causative factors in this disease.4 In
addition, the role of the HLA-B51 gene in genetic suscept-
ibility to Behcet’s Disease has been defined in recent years.5-6
Vitamin D has long been known to be important for bone
health and turnover.7 In recent studies, vitamin D has been
demonstrated to play a significant role in malignancy,
immune system functioning, and cardiovascular events.8-10
The measurement of serum 25-hydroxyvitamin D levels,
commonly used by clinicians, is accepted as a clinical
indicator of vitamin D status because of its correlation with
low vitamin D values.11 The metabolite 1,25-dihydroxyvita-
min D is formed by 1-hydroxylation of 25-hydroxyvitamin
D in the kidneys.8 Although it is the active metabolite of
vitamin D, 1,25-dihydroxyvitamin D serum values do not
correlate well with vitamin D deficiency. Therefore, these
values are not preferred for routine testing of vitamin D
levels.
Vitamin D deficiency is particularly common in patients with
rheumatological disorders, such as rheumatoid arthritis (RA)
and systemic lupus erythematosus (SLE).12 Vitamin D status
has been inversely correlated with disease activity in those
disorders due to the immunomodulatory effects of vitamin
D.13,14 Vitamin D has been proposed as a new preventive
treatment of inflammatory diseases. Environmental and inflam-
matory factors, renal and hepatic involvement, and certain
drugs could be involved in the pathophysiology of vitamin D
deficiency in rheumatological disorders.15
To our knowledge, vitamin D levels have not been
previously studied in Behcet’s Disease. The aim of this
study was to characterize the vitamin D status of patients
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with Behcet’s Disease and the relationship between vitamin
D levels and the inflammatory process.
MATERIALS AND METHODS
The diagnostic criteria for Behcet’s Disease proposed by
the International Study Group for Behcet’s Disease were
used for diagnosis.16 Thirty-two patients with Behcet’s
Disease and thirty-one matched healthy controls were
included in the study. All participants were informed of
the study protocol, and their written informed consent was
obtained according to the Declaration of Helsinki. The study
was approved by the local ethics committee of Ataturk
University.
Subjects in the patient and control groups with a history
of liver and kidney diseases, diabetes mellitus, familial
hypercholesterolemia, thyroid and parathyroid diseases,
and malignancy were excluded from the study. Individuals
with osteoporosis or a history of osteoporosis treatment,
liver and kidney diseases, endocrine diseases, and post-
menopausal women were excluded from the study.
In the study group, three patients were on active phase of
the disease. Twenty-seven of the patients were under
colchicine therapy at doses of 1 to 1.5 mg/day, and two
patients were taking colchicine along with low-dose
steroids. Three patients had a history of steroid use.
The heights and weights of all subjects were on recorded,
and body mass index (BMI) was calculated as weight (kg)/
height (m2). Laboratory testing of serum calcium (Ca),
phosphate (P), total alkaline phosphatase (ALP), and 25-
hydroxyvitamin D levels was conducted for all patients and
control subjects. The erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP) level were determined in whole
blood and serum aliquots, respectively. ESR was determined
according to the Westergren method and CRP by a
nephelometric method (Beckman Array Protein System,
USA). 25-hydroxyvitamin D levels were determined in an
E-170 ECL system (Roche, Japan) with an electrochemilumi-
nescence method.
Statistical Analysis
Statistical analysis was performed with PASW Statistics
18 (SPSS Inc., Chicago, U.S.A.) for Windows. Statistical
analyses were performed using the Mann-Whitney U test. A
p value of less than 0.05 was accepted as statistically
significant. Correlations among parameters were analyzed
using Pearson’s correlation coefficient. A multivariable
regression model was established to evaluate the effects of
different variables on vitamin D levels.
RESULTS
Table I lists the clinical and demographic characteristics of
the patient and control groups. The findings are expressed as
median (min-max). The demographic and BMI values were
similar between groups. The acute-phase reactant levels of
ESR and CRP were significantly higher in patients with
Behcet’s Disease than in the control subjects (p,0.05).
After the data were weighted by age, vitamin D levels
were significantly lower in the patient group than in the
control group (p,0.001). There was no significant difference
between the patients and the controls in terms of Ca, P, or
ALP levels (p.0.05). There was no correlation between
vitamin D levels and age, BMI, disease duration, ESR, or
CRP levels (Table II). Multivariable regression analysis was
performed to determine the main predictors of vitamin D
levels (Table III). The variables included in the model were
age, smoking, alcohol intake, and use of colchicine and
corticosteroid drugs. Age, smoking, alcohol intake, and use
of colchicine were found to be the main predictors.
Colchicine therapy was found to have the greatest effect
on levels of vitamin D (p,0.001). We did not find a
significant relationship between the use of steroids and 25-
hydroxyvitamin D (p = 0.62).
DISCUSSION
Behcet’s Disease is a systemic and immunoinflammatory
form of vasculitis with endothelial dysfunction.17 The
inflammation is generally mediated by cytokines derived
from Th1 lymphocytes, such as tumour necrosis factor-a
(TNF-a), interleukin-6 (IL-6), and IL-18.18 Vitamin D is a
hormone that has important roles in calcium homeostasis
and bone turnover.19 There is an increasing interest in the
relationship between vitamin D deficiency and a number of
autoimmune diseases.12
Decreased vitamin D levels have been reported to correlate
with increased SLE disease activity.14 Animal model studies of
SLE have shown that some aspects of the disease decreased in
severity when vitamin D intake was increased.20 Vitamin D has
also been related to disease activity in RA. Values of 25-
hydroxyvitamin D and 1,25-dihydroxyvitamin D showed
significant negative correlations with RA disease activity.13,21
Vitamin D has immunosuppressant properties and has been
considered as a therapeutic intervention for several auto-
immune diseases.22 In an in vitro study, Do et al.23 showed
Table I - Clinical and laboratory features of patients with
Behcet’s Disease and healthy controls.
Patient group Control group p-value
Sex (male/female) 14/18 11/20 ns
Age (years) 29 (18-50) 33 (21-57) ns
Disease duration
(months)
33 (3-216) -
Height (cm) 164.5 (143-183) 162 (150-182) ns
Weight (kg) 65.5 (43-92) 66 (50-95) ns
BMI (kg/m2) 24.7 (16.8-30.5) 25.4 (19.5-33.5) ns
Pathergy test
positivity (%)
14 (43.8 %) -
ESR (mm/h) 13.5 (1-89) 10 (2-25) p,0.05
CRP (mg/L) 0.5 (0.3-12.6) 0.3 (0.3-1.1) p,0.05
Ca (mg/dl) 9.4 (8.1-10.5) 9.4 (8.5-10.6) ns
P (mg/dl) 3.5 (2.6-5.3) 3.5 (2.7-5.3) ns
ALP (U/L) 84 (38-167) 76 (42-141) ns
25-hydroxyvitamin
D (ng/ml)
13.76 (4-35.79) 18.97 (12.05-36.94) p,0.001
ns: not significant.
Table II - Correlation between 25-hydroxyvitamin D levels
and clinical parameters in patients with Behcet’s Disease.
Median (min-max) r p-value
Age (years) 29 (18-50) 0.126 ns
BMI (kg/m2) 24.7 (16.8-30.5) 0.323 ns
Disease duration
(months)
33 (3-216) 0.303 ns
ESR (mm/h) 13.5 (1-89) 0.258 ns
CRP (mg/L) 0.5 (0.3-12.6) 0.244 ns
ns: not significant.
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that vitamin D suppressed the expression of Toll-like receptor
(TLR) in monocytes of patients with Behcet’s Disease. They
also reported that vitamin D may be useful as a therapeutic
option for inflammation triggered through TLR2 and TLR4,
which are important in the pathogenesis of Behcet’s Disease.
In this study, we demonstrated that serum 25-hydro-
xyvitamin D levels were lower in patients with Behcet’s
Disease than in the control subjects. To our knowledge,
serum 25-hydroxyvitamin D levels have not previously
been investigated in patients with Behcet’s Disease.
The pathogenesis of vitamin D deficiency is not clearly
understood. Several factors, such as impaired calcium and
vitamin D intake, malnutrition, smoking, alcohol consumption,
inadequate sunlight exposure, hypogonadism, aging, corticos-
teroid therapy, and impaired physical activity, may play an
important roles in the etiopathogenesis of vitamin D deficiency.
Increased metabolism or impaired 25-hydroxylation induced
by medication or by disease involvement may affect vitamin D
values.24 In addition, the inhibition of 1-a-hydroxylase by TNF-
a may contribute to lower vitamin D levels.25
In this study, we found that age, smoking, alcohol intake,
and use of colchicine were the main predictors of 25-
hydroxyvitamin D levels. Colchicine treatment was the most
effective predictor of 25-hydroxyvitamin D values. The
effects of colchicine on 25-hydroxyvitamin D levels have not
yet been fully defined in the literature.
This study had several limitations. First, the number of
patients was small. Second, most of the patients were using
colchicine, and it is not known whether colchicine affects 25-
hydroxyvitamin D levels. Thus, it would be optimal to
measure 25-hydroxyvitamin D concentrations before colchi-
cine use. Third, although we did not find a significant
relationship between the use of steroids and 25-hydroxyvi-
tamin D, the number of subjects using corticosteroids was
small, which may have affected the results. Fourth, serum
parathyroid hormone (PTH) levels, calcium intake, physical
activity, and sun exposure were not analyzed.
In conclusion, serum 25-hydroxyvitamin D levels are
decreased in patients with Behcet’s Disease. Smoking, alcohol
intake, and use of colchicine are predictive of low 25-
hydroxyvitamin D levels. Future interventional studies are
needed to determine the efficacy of 25-hydroxyvitamin D in
patients with Behcet’s Disease.
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